Capricor Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $374.45 million, with shareholders equity totaling $246.22 million.
The company employs approximately 26 people and operates in the Health Care sector, within the Biotechnology industry.
Over the past 12 months, Capricor Therapeutics Inc. reported $- in revenue, generating net income of $-129.41 million.
Key financial metrics include a P/E ratio of -2.89, a price-to-book (P/B) ratio of 1.52, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker CAPR.